BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
(Q29617585)
scientific article (publication date: October 2004)
scientific article (publication date: October 2004)
Language: